CorMedix (CRMD)
(Delayed Data from NSDQ)
$4.71 USD
-0.06 (-1.26%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $4.70 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CRMD 4.71 -0.06(-1.26%)
Will CRMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRMD
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
CRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
How Much Upside is Left in CorMedix (CRMD)? Wall Street Analysts Think 198.21%
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
Other News for CRMD
CorMedix price target lowered by $2 at Truist, here's why
CorMedix Inc. Announces Outpatient Availability of DefenCath
Truist Financial Sticks to Its Buy Rating for Cormedix (CRMD)
Buy Rating for CorMedix Supported by DefenCath’s Market Potential and FDA Advancements
CorMedix to start DefenCath label expansion program this year